JP2023523429A5 - - Google Patents

Info

Publication number
JP2023523429A5
JP2023523429A5 JP2022564508A JP2022564508A JP2023523429A5 JP 2023523429 A5 JP2023523429 A5 JP 2023523429A5 JP 2022564508 A JP2022564508 A JP 2022564508A JP 2022564508 A JP2022564508 A JP 2022564508A JP 2023523429 A5 JP2023523429 A5 JP 2023523429A5
Authority
JP
Japan
Prior art keywords
cells
approximately
enriched
composition
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022564508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523429A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/028504 external-priority patent/WO2021216790A1/en
Publication of JP2023523429A publication Critical patent/JP2023523429A/ja
Publication of JP2023523429A5 publication Critical patent/JP2023523429A5/ja
Pending legal-status Critical Current

Links

JP2022564508A 2020-04-22 2021-04-21 ナチュラルキラー(nk)細胞組成物およびそれを生成させるための方法 Pending JP2023523429A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014056P 2020-04-22 2020-04-22
US63/014,056 2020-04-22
PCT/US2021/028504 WO2021216790A1 (en) 2020-04-22 2021-04-21 Natural killer (nk) cell compositions and methods for generating same

Publications (2)

Publication Number Publication Date
JP2023523429A JP2023523429A (ja) 2023-06-05
JP2023523429A5 true JP2023523429A5 (enExample) 2024-05-02

Family

ID=75787369

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022564508A Pending JP2023523429A (ja) 2020-04-22 2021-04-21 ナチュラルキラー(nk)細胞組成物およびそれを生成させるための方法

Country Status (8)

Country Link
US (1) US20230190801A1 (enExample)
EP (1) EP4139439A1 (enExample)
JP (1) JP2023523429A (enExample)
KR (1) KR20230088306A (enExample)
CN (1) CN116368221A (enExample)
AU (1) AU2021258194A1 (enExample)
CA (1) CA3180658A1 (enExample)
WO (1) WO2021216790A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4171617A1 (en) 2020-06-30 2023-05-03 Mendus B.V. Use of leukemia-derived cells in ovarian cancer vaccines
JP2024506249A (ja) 2021-01-22 2024-02-13 メンドゥス・ベスローテン・フェンノートシャップ 腫瘍ワクチン接種の方法
US20240002800A1 (en) * 2022-05-16 2024-01-04 Mendus B.V. Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy
CN115044552A (zh) * 2022-08-11 2022-09-13 启朔(北京)生物科技有限公司 一种自然杀伤细胞的体外培养方法及试剂盒
WO2024243058A1 (en) * 2023-05-19 2024-11-28 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and bendamustine
WO2025213127A1 (en) 2024-04-05 2025-10-09 Indapta Therapeutics, Inc. Treatment of autoimmune diseases or conditions with natural killer cells
WO2025245399A1 (en) 2024-05-23 2025-11-27 Indapta Therapeutics, Inc. Method of treating cancer with natural killer cells

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US20020159979A1 (en) 1994-06-06 2002-10-31 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
FR2735789B1 (fr) 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
US6632670B1 (en) 1995-09-08 2003-10-14 Genzyme Corporation AAV vectors for gene therapy
US7001765B2 (en) 1996-03-06 2006-02-21 Medigene Ag Adeno-associated virus vector for boosting immunogenicity of cells
EP1012236A1 (en) 1997-08-15 2000-06-28 Rubicon Laboratory Inc. Retrovirus and viral vectors
EP1015619A1 (en) 1997-09-19 2000-07-05 The Trustees Of The University Of Pennsylvania Methods and cell line useful for production of recombinant adeno-associated viruses
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
US6436392B1 (en) 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
US20040063094A1 (en) 1998-05-20 2004-04-01 Biovex Limited Mutant herpes simplex viruses and uses thereof
US6016891A (en) 1998-08-10 2000-01-25 Sava; John G. Tree stand harness system
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
GB9904582D0 (en) 1999-02-26 1999-04-21 Nycomed Imaging As Process
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
DE19933288A1 (de) 1999-07-15 2001-01-18 Medigene Ag Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
US7241447B1 (en) 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
AU2584901A (en) 1999-12-22 2001-07-03 Onyx Pharmaceuticals, Inc. Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth
GB2375113B (en) 2000-01-21 2004-10-20 Biovex Ltd A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US6653103B2 (en) 2001-03-30 2003-11-25 Wisconsin Alumni Research Foundation Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
HUP0400882A3 (en) 2001-05-11 2011-01-28 Wellstat Biologics Corp Oncolytic virus therapy
CA2452517A1 (en) 2001-07-11 2003-01-23 University Of Miami Recombinant vsv for the treatment of tumor cells
AU2003258060B2 (en) 2002-03-27 2007-07-12 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
US20030225260A1 (en) 2002-04-30 2003-12-04 Snyder Richard O. Production of recombinant AAV virions
US20050220818A1 (en) 2002-06-21 2005-10-06 Wellstat Biologics Corporation Administration of therapeutic viruses
AU2003268505A1 (en) 2002-09-09 2004-03-29 University Of Tennessee Research Foundation Recombinatant mutants of rhabdovirus and methods of use thereof
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
JP2007524363A (ja) 2003-03-27 2007-08-30 オタワ ヘルス リサーチ インスティチュート 変異体水疱性口内炎ウイルスおよびそれらの使用
ATE420160T1 (de) 2003-06-18 2009-01-15 Genelux Corp Modifizierte rekombinante vacciniaviren, verwendungen davon
EP2345731B1 (en) 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
US20070003520A1 (en) 2003-11-17 2007-01-04 Brown Susanne M Mutant viruses
WO2005116224A2 (en) 2004-05-18 2005-12-08 Children's Memorial Hospital Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
US20090208924A1 (en) 2004-12-01 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Generation of Replication Competent Viruses for Therapeutic Use
EP1885186B1 (en) 2005-06-01 2015-09-02 California Institute Of Technology Method of targeted gene delivery using viral vectors
AU2006262021C1 (en) 2005-06-23 2012-05-10 The University Of Houston Use of mutant Herpes Simplex Virus-2 for cancer therapy
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
GB0522476D0 (en) 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
EP2097517B1 (en) 2006-10-16 2014-06-04 Genelux Corporation Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody
US20100178684A1 (en) 2006-12-21 2010-07-15 Woo Savio L C Transgenic oncolytic viruses and uses thereof
GB2446721B (en) 2007-02-16 2009-03-25 Crusade Lab Ltd Herpes simplex viruses and methods of viral replication
CA2690627C (en) 2007-06-15 2014-12-02 Genelux Corporation Microorganisms for imaging and/or treatment of tumors
JP2010533718A (ja) 2007-07-18 2010-10-28 ジェネラックス・コーポレイション 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
WO2009054996A2 (en) 2007-10-25 2009-04-30 Genelux Corporation Systems and methods for viral therapy
US8313896B2 (en) 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
US20120052003A9 (en) 2008-05-16 2012-03-01 Szalay Aladar A Microorganisms for preventing and treating neoplasms accompanying cellular therapy
WO2009148488A2 (en) 2008-05-29 2009-12-10 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
US8481297B2 (en) 2009-01-08 2013-07-09 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
WO2012061814A1 (en) 2010-11-05 2012-05-10 Transgenomic, Inc. Pcr primers and methods for rapid and specific genotyping
US10066207B2 (en) 2012-04-18 2018-09-04 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
EP3539552A1 (en) * 2018-03-16 2019-09-18 Deutsches Rheuma-Forschungszentrum Berlin Activation and expansion of nkg2c+ nk cells
AU2019271146A1 (en) * 2018-05-14 2020-12-10 Indapta Therapeutics, Inc. Subsets of human natural killer cells with enhanced antibody-directed immune responses
EP3884041A2 (en) * 2018-11-21 2021-09-29 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
US20240316102A1 (en) * 2021-07-01 2024-09-26 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods

Similar Documents

Publication Publication Date Title
JP2023523429A5 (enExample)
Wu et al. Developmental and functional control of natural killer cells by cytokines
Vokali et al. Lymphatic endothelial cells prime naïve CD8+ T cells into memory cells under steady-state conditions
Coates et al. Dendritic cell subsets in blood and lymphoid tissue of rhesus monkeys and their mobilization with Flt3 ligand
KR100943087B1 (ko) 면역치료용 활성화 림프구 제조방법
Morris et al. Advances in the understanding of acute graft‐versus‐host disease
JP2024527559A5 (enExample)
JPH06508613A (ja) 自己移植の改良法
CN115558641B (zh) 高纯度效应免疫细胞群及其培养方法、试剂组合物和应用
CN116490607A (zh) 肿瘤浸润淋巴细胞培养基及其应用
KR20220031541A (ko) 항-bcma car t 세포의 제조
US20210361711A1 (en) CIML NK cells and Methods Therefor
CN115651903B (zh) 高杀伤力的免疫细胞群及其培养方法、试剂组合物和应用
WO2001038494A1 (en) Method of proliferating natural killer cells
AU2022230374B2 (en) Highly potent m-cenk cells and methods
CA3117134A1 (en) Ciml nk cells and methods therefor
CN1444648A (zh) 扩增自然杀伤t细胞的方法
JPH08509859A (ja) TGF−βの中和による長期骨髄培養物における幹細胞の拡大
AU782937B2 (en) Cell composition containing macrophages, presenting anti-infectious and hematopoietic properties, and a process for preparing the same
US20240025990A1 (en) Prevention and treatment of graft-versus-host disease (gvhd)
RU2851449C1 (ru) Новое лечение сепсиса
CN117120596A (zh) 高效的m-cenk细胞和方法
WO2025218187A1 (zh) 基因编辑的肿瘤浸润淋巴细胞和t细胞受体工程化t细胞及其在免疫治疗中的应用
Singh Determining Differential Effects of Interleukin-2 on Innate and Adaptive Immune Cells in Lymphoid Organs and the Gastrointestinal Tract
Li A study of human mast cell origin and differentiation